

# What to Expect With YORVIPATH®

This brochure will help you understand what to expect when starting YORVIPATH, including who to contact for help along the way.

#### IMPORTANT SAFETY INFORMATION AND USE

#### What is YORVIPATH® used for?

YORVIPATH is a prescription medicine used to treat adults with low parathyroid hormone (PTH) (hypoparathyroidism).

- It is not known if YORVIPATH is safe and effective in people who have been
  recently diagnosed with hypoparathyroidism after surgery, or if it is started
  in people with low levels of calcium in the blood.
- It is not known if YORVIPATH is safe and effective in children.
- YORVIPATH should not be used in children and young adults whose bones are still growing.

Please see Important Safety Information throughout and accompanying full Prescribing Information for YORVIPATH and the Medication Guide.

### What Is YORVIPATH®?

# What Should I Know About Taking YORVIPATH?



YORVIPATH is a ready-to-use, once-daily injection delivering active PTH over 24 hours.

YORVIPATH is designed to address your hypoparathyroidism with individualized dosing.

YORVIPATH will be titrated by your doctor to find **your** individual dose. The goal of titration is to find the dose needed to maintain normal calcium levels without active vitamin D and calcium (known as conventional therapy).

PTH = parathyroid hormone.

#### IMPORTANT SAFETY INFORMATION AND USE

What is the most important information I should know about YORVIPATH? YORVIPATH may cause serious side effects, including:

- High levels of calcium in the blood (hypercalcemia). YORVIPATH can cause some people to have higher blood calcium levels than normal. Your healthcare provider should check your blood calcium before you start and during your treatment with YORVIPATH. Tell your healthcare provider right away if you have nausea, vomiting, dizziness, feeling thirsty, confusion, muscle weakness, or irregular heartbeat. Hypercalcemia is more likely to occur within the first 3 months of starting YORVIPATH, but it may occur at any time.
- Low levels of calcium in the blood (hypocalcemia). People who stop using, miss, or change a dose of YORVIPATH may have an increased risk of low blood calcium levels, but hypocalcemia may occur at any time. Tell your healthcare provider right away if you have tingling in your fingertips, toes, lips or tongue, muscle spasms or cramps, oral numbness, depression, have problems thinking or remembering, abnormal heart rhythms, or seizures.



Each YORVIPATH pen is prefilled and ready to use.



Until first use, store your pens in the refrigerator between 2°C to 8°C (36°F to 46°F).



After your pen is used for the first time, it can be left at room temperature for 14 days.



You must properly discard your pen in an FDA-cleared sharps container on the 14th day, even if it still has medicine inside.



It is important to take your YORVIPATH injection as your doctor directed at the same time every day, whether you choose to inject during the day or at night.

#### IMPORTANT SAFETY INFORMATION AND USE

• **Possible bone cancer (osteosarcoma).** Tell your healthcare provider right away if you have pain in any areas of your body that does not go away or any new or unusual lumps or swelling under your skin that is tender to touch. These are some of the signs and symptoms of osteosarcoma and your healthcare provider may need to do further tests.

#### Who should not take YORVIPATH?


Do not use YORVIPATH if you are allergic to palopegteriparatide or any of the other ingredients in YORVIPATH.

Please see Important Safety Information throughout and accompanying full Prescribing Information for YORVIPATH and the Medication Guide.



### Getting to Know Your YORVIPATH® Pen

#### Parts overview



\*Depending on your pen, the dose window will show 6, 9, or 12 mcg; 15, 18, or 21 mcg; or 24, 27, or 30 mcg.

#### IMPORTANT SAFETY INFORMATION AND USE

#### What should I tell my healthcare provider before taking YORVIPATH?

Before using YORVIPATH, tell your healthcare provider about all of your medical conditions, including if you:

- are at higher risk of a type of bone cancer called osteosarcoma. This is especially important:
  - if you have a bone disease that increases your risk of developing osteosarcoma (including if you have Paget's disease).
  - if a blood test shows that you have unexplained increases in bone alkaline phosphatase.
  - if you have cancer of the bones or other cancer that has spread to your bones.
  - if you are having or have had radiation therapy to the skeleton.
  - if you are affected with a condition that runs in your family that can increase your chance of getting cancer in your bones.

### **Individualized Dosing**

#### Your dosing timeline

At the start of treatment, your doctor will work with you to find your daily YORVIPATH dose. It may take time to find your individualized dose, as dose adjustments and lab work may be required.

#### Here is how you and your doctor will find the dose that works for you:

**Checking your lab values.** Before you start YORVIPATH, your doctor will make sure your vitamin D and calcium levels are in range. Your doctor will also monitor your blood calcium levels within 7 to 10 days of starting YORVIPATH and when adjustments are made to your doses of YORVIPATH, calcium, and/or active vitamin D.

**Starting YORVIPATH**. You will start your daily YORVIPATH injections at the dose prescribed by your doctor. Your doctor may also adjust your calcium and/or active vitamin D doses on the same day you start YORVIPATH.

**Adjusting your dose**. Based on your labs, your doctor may adjust your dose of YORVIPATH, calcium, and/or vitamin D.

**Maintaining your dose.** Once your individualized dose has been found, you will continue lab work every 4 to 6 weeks as directed by your doctor.

#### IMPORTANT SAFETY INFORMATION AND USE

- take medicines that contain digoxin, are used to treat osteoporosis, or can affect calcium levels in your blood.
- are pregnant or plan to become pregnant. It is not known if YORVIPATH will harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with YORVIPATH.
- are breastfeeding or plan to breastfeed. It is not known if YORVIPATH passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with YORVIPATH.

Please see Important Safety Information throughout and accompanying full Prescribing Information for YORVIPATH and the Medication Guide.



# The Ascendis Signature Access Program® (A·S·A·P)

### How A·S·A·P supports you

A·S·A·P is a program that provides services throughout your care.\* **Once enrolled, this may include**:



A dedicated Nurse Advocate assigned to you



A treatment Starter Kit with Instructions for Use



Assistance with the insurance process



Working to avoid a gap in treatment



Help seeking financial assistance when needed to pay for YORVIPATH®

### IMPORTANT SAFETY INFORMATION AND USE

**Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. YORVIPATH and other medicines may affect each other causing side effects.

#### What are the possible side effects of YORVIPATH?

#### YORVIPATH may cause serious side effects:

- Allergic (hypersensitivity) reaction, including anaphylaxis. Stop taking YORVIPATH and tell your healthcare provider or get emergency medical help right away if you have swelling of your face, lips, mouth, or tongue, breathing problems, fainting, dizziness, feeling lightheaded (low blood pressure), fast heartbeat, itching, rash, or hives.
- Decrease in blood pressure when you change positions (orthostatic hypotension). Some people may feel dizzy, get a fast heartbeat, or feel light-headed right after injecting YORVIPATH. For the first few doses, give your injection of YORVIPATH in a place where you can sit or lie down right away if you get these symptoms. If your symptoms get worse or do not go away, contact your healthcare provider before you continue using YORVIPATH.
- **Digoxin toxicity if you are using digoxin and YORVIPATH at the same time.** Tell your healthcare provider if you experience irregular heart rhythm, heart palpitations, confusion, loss of appetite, nausea, vomiting, diarrhea, or vision problems.

**The most common side effects of YORVIPATH include** injection site reactions, vasodilatory signs or symptoms such as a drop in blood pressure or lightheadedness when standing up, headache, diarrhea, back pain, high calcium levels, and sore throat.

These are not all of the possible side effects of YORVIPATH. Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.



\*The A·S·A·P program provides patient support services to eligible patients who were prescribed YORVIPATH for its approved indication. Please see Important Safety Information throughout and accompanying full Prescribing Information for YORVIPATH and the Medication Guide.



# Your Next Step With YORVIPATH®



With YORVIPATH, you are ready to take the next step in your hypoparathyroidism journey. We are here to support you throughout your treatment.



For personalized support or to learn more, call **1-844-442-7236** (available from 8 AM to 8 PM ET, Monday through Friday) and follow the prompts to reach A·S·A·P.



Scan the QR code or visit Yorvipath.com/how-to-use to watch a video with step-by-step instructions for using YORVIPATH.

### IMPORTANT SAFETY INFORMATION AND USE

#### What is the most important information I should know about YORVIPATH? YORVIPATH may cause serious side effects, including:

• High levels of calcium in the blood (hypercalcemia). YORVIPATH can cause some people to have higher blood calcium levels than normal. Your healthcare provider should check your blood calcium before you start and during your treatment with YORVIPATH. Tell your healthcare provider right away if you have nausea, vomiting, dizziness, feeling thirsty, confusion, muscle weakness, or irregular heartbeat. Hypercalcemia is more likely to occur within the first 3 months of starting YORVIPATH, but it may occur at any time.

Please see Important Safety Information throughout and accompanying full Prescribing Information for YORVIPATH and the Medication Guide.



© September 2024 Ascendis Pharma Endocrinology, Inc. All rights reserved. YORVIPATH®, Ascendis Signature Access Program®, Ascendis®, the Ascendis Pharma logo and the company logo are trademarks owned by the Ascendis Pharma Group. US-COMMPTH-2300089 09/24